INVO Bioscience Inc
INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.
INVO Bioscience Inc (INVO) - Net Assets
Latest net assets as of September 2024: $-23.32K USD
Based on the latest financial reports, INVO Bioscience Inc (INVO) has net assets worth $-23.32K USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($17.02 Million) and total liabilities ($17.04 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-23.32K |
| % of Total Assets | -0.14% |
| Annual Growth Rate | 20.49% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 1083.88 |
INVO Bioscience Inc - Net Assets Trend (2006–2023)
This chart illustrates how INVO Bioscience Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for INVO Bioscience Inc (2006–2023)
The table below shows the annual net assets of INVO Bioscience Inc from 2006 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $892.83K | +191.33% |
| 2022-12-31 | $-977.61K | -113.37% |
| 2021-12-31 | $7.31 Million | +27.29% |
| 2020-12-31 | $5.74 Million | +254.65% |
| 2019-12-31 | $-3.71 Million | -36.32% |
| 2018-12-31 | $-2.72 Million | +45.43% |
| 2017-12-31 | $-4.99 Million | -32.87% |
| 2016-12-31 | $-3.76 Million | 0.00% |
| 2015-12-31 | $-3.76 Million | +13.81% |
| 2014-12-31 | $-4.36 Million | -14.26% |
| 2013-12-31 | $-3.81 Million | -13.11% |
| 2012-12-31 | $-3.37 Million | -15.30% |
| 2011-12-31 | $-2.93 Million | -17.86% |
| 2010-12-31 | $-2.48 Million | +23.33% |
| 2009-12-31 | $-3.24 Million | -378.47% |
| 2008-12-31 | $-676.57K | -2537.82% |
| 2007-12-31 | $27.75K | -26.07% |
| 2006-12-31 | $37.54K | -- |
Equity Component Analysis
This analysis shows how different components contribute to INVO Bioscience Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5780995900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $249.00 | 0.03% |
| Other Comprehensive Income | $-6.00 Million | -672.02% |
| Other Components | $64.71 Million | 7247.86% |
| Total Equity | $892.83K | 100.00% |
INVO Bioscience Inc Competitors by Market Cap
The table below lists competitors of INVO Bioscience Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
InnSuites Hospitality Trust
NYSE MKT:IHT
|
$2.91 Million |
|
Loyal Textile Mills Limited
NSE:LOYALTEX
|
$2.91 Million |
|
Delivra Health Brands Inc
OTCQB:DHBUF
|
$2.91 Million |
|
EATON CORP -NPV-
MU:3EC
|
$2.91 Million |
|
Joy Industrial Co., Ltd.
TWO:4559
|
$2.91 Million |
|
MODIVCARE INC. DL-001
F:PRF0
|
$2.91 Million |
|
LTI0
F:LTI0
|
$2.91 Million |
|
Sulliden Minerals SA
TO:SMC
|
$2.90 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in INVO Bioscience Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -977,612 to 892,825, a change of 1,870,437.
- Net loss of 8,034,612 reduced equity.
- New share issuances of 5,725,000 increased equity.
- Other comprehensive income decreased equity by 6,000,000.
- Other factors increased equity by 10,180,049.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.03 Million | -899.91% |
| Share Issuances | $5.72 Million | +641.22% |
| Other Comprehensive Income | $-6.00 Million | -672.02% |
| Other Changes | $10.18 Million | +1140.21% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares INVO Bioscience Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.32x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 23.05x to 1.32x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | $0.03 | $0.75 | x |
| 2007-12-31 | $0.02 | $0.75 | x |
| 2008-12-31 | $-0.59 | $0.75 | x |
| 2009-12-31 | $-1.89 | $0.75 | x |
| 2010-12-31 | $-1.25 | $0.75 | x |
| 2011-12-31 | $-1.13 | $0.75 | x |
| 2012-12-31 | $-1.30 | $0.75 | x |
| 2013-12-31 | $-1.47 | $0.75 | x |
| 2014-12-31 | $-1.68 | $0.75 | x |
| 2015-12-31 | $-0.88 | $0.75 | x |
| 2016-12-31 | $-0.88 | $0.75 | x |
| 2017-12-31 | $-1.12 | $0.75 | x |
| 2018-12-31 | $-0.56 | $0.75 | x |
| 2019-12-31 | $-15.30 | $0.75 | x |
| 2020-12-31 | $20.92 | $0.75 | x |
| 2021-12-31 | $13.75 | $0.75 | x |
| 2022-12-31 | $-1.61 | $0.75 | x |
| 2023-12-31 | $0.57 | $0.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently INVO Bioscience Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -899.91%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -266.00%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 23.40x
- Recent ROE (-899.91%) is below the historical average (-72.90%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | -19.68% | 0.00% | 0.00x | 1.01x | $-11.14K |
| 2007 | -156.33% | 0.00% | 0.00x | 1.08x | $-46.16K |
| 2008 | 0.00% | -4930.66% | 0.12x | 0.00x | $-1.81 Million |
| 2009 | 0.00% | -7375.28% | 0.22x | 0.00x | $-4.34 Million |
| 2010 | 0.00% | -226.81% | 0.37x | 0.00x | $94.76K |
| 2011 | 0.00% | -1115.30% | 0.56x | 0.00x | $-504.94K |
| 2012 | 0.00% | -1182.14% | 0.45x | 0.00x | $-329.18K |
| 2013 | 0.00% | -2810.77% | 0.22x | 0.00x | $-379.20K |
| 2014 | 0.00% | -10444.13% | 0.15x | 0.00x | $-1.30 Million |
| 2015 | 0.00% | -42426.61% | 0.02x | 0.00x | $-4.58 Million |
| 2016 | 0.00% | -42426.61% | 0.02x | 0.00x | $-4.58 Million |
| 2017 | 0.00% | -248.87% | 1.06x | 0.00x | $-202.95K |
| 2018 | 0.00% | -622.22% | 0.64x | 0.00x | $-2.80 Million |
| 2019 | 0.00% | -146.43% | 0.82x | 0.00x | $-1.80 Million |
| 2020 | -145.34% | -804.73% | 0.09x | 1.91x | $-8.92 Million |
| 2021 | -91.03% | -159.97% | 0.40x | 1.43x | $-7.39 Million |
| 2022 | 0.00% | -1324.81% | 0.20x | 0.00x | $-10.79 Million |
| 2023 | -899.91% | -266.00% | 0.14x | 23.40x | $-8.12 Million |
Industry Comparison
This section compares INVO Bioscience Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| INVO Bioscience Inc (INVO) | $-23.32K | -19.68% | N/A | $2.91 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |